Akzo Nobel stock has delivered a decline of almost 30% over the past 5 years, yet current valuation checks suggest the shares may now trade at a discount to their estimated intrinsic value. With both a Discounted Cash Flow (DCF) estimate and market multiples pointing in the same direction, investors are weighing whether that gap is meaningful or a value trap.
-
The roughly 29.6% share price decline over 5 years means long term holders have seen capital erode, which can sometimes leave a stock out of favour relative to its fundamentals.
-
The planned merger with Axalta, including the appointment of a combined Board, can support expectations for better scale and cash generation. However, integration execution and any disruption to customer relationships may cap how much value investors are willing to assign upfront.
-
Akzo Nobel currently screens as cheap on the broader checks, with a high value score of 5 out of 6 and an intrinsic value estimate that is about 41.5% above the recent share price.
The issue now is whether Akzo Nobel's discount to its intrinsic value estimate offers enough compensation for the risks around execution and future cash flows.
Compare Akzo Nobel's valuation reset with other potential opportunities by scanning 262 high quality undervalued stocks that also pair discounted prices with solid fundamentals.
Does Akzo Nobel Look Undervalued on Cash Flow?
The Discounted Cash Flow (DCF) model estimates what Akzo Nobel is worth based on the cash it is expected to generate for shareholders. For Akzo Nobel, the model starts from latest twelve month free cash flow of about €590 million and assumes these cash flows keep growing rather than shrinking, then applies a 2 stage Free Cash Flow to Equity approach to reflect a more gradual long term pattern.
On this basis, the model points to an intrinsic value of about €105.53 per share, which is roughly 41.5% above the recent share price. The pending merger with Axalta and the announcement of the combined Board help explain why some investors may question how reliable these cash flow projections are, because integration outcomes can influence future free cash flow delivery. Even with that uncertainty, the DCF output suggests the market price builds in a sizeable margin against the cash flows currently modeled for Akzo Nobel.
Overall, the Discounted Cash Flow assessment indicates Akzo Nobel stock currently looks undervalued relative to its modeled cash generation.
Our Discounted Cash Flow (DCF) analysis suggests Akzo Nobel is undervalued by 41.5%. Track this in your watchlist or portfolio , or discover 262 more high quality undervalued stocks .
Does Akzo Nobel Look Undervalued on Earnings?
The P/E ratio is a useful cross check for Akzo Nobel because earnings are a key focus for coatings and chemicals companies. It provides a simple way to compare what the market is paying for each euro of profit.
Akzo Nobel currently trades on a P/E of about 16.6x. This is below the Chemicals industry average of roughly 20.3x and well under the peer group average of about 37.4x. On Simply Wall St's fair P/E estimate of around 21.0x, which adjusts for factors such as margins, growth expectations and risk, the stock trades at a discount that indicates the market is applying a more cautious view than this model implies.
This gap means the current share price reflects lower expectations than those implied by the fair P/E benchmark, even after accounting for sector comparisons. For investors who are comfortable with Akzo Nobel's earnings profile and the pending Axalta merger, that lower multiple may warrant further research.
On the P/E multiple, Akzo Nobel stock appears inexpensive relative to both its industry and its modeled fair ratio.
See what the numbers say about this price — find out in our valuation breakdown.
The Akzo Nobel Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up from the valuation puzzle around Akzo Nobel's stock and spell out which paths for growth, margins and earnings would need to hold for the shares to be worth materially more or less than today's price. Each one sets out Akzo Nobel's fair value as a thesis about the business that you can track over time, rather than treating it as a one off snapshot, and they live on the company's Community page.
The community is split on Akzo Nobel, with one camp seeing efficiency gains and a sustainability focus as support for value, while the other worries merger execution could cap returns.
Bull case: roughly fairly valued
"The company is capitalizing on accelerating demand for sustainable and eco-friendly coatings, highlighted by their leadership position in low-VOC and sustainable product innovations, which are set to drive premium pricing and increase net margins as regulatory and consumer preferences shift further toward sustainability…"
Read the full Bull Case to see why Akzo Nobel could be undervalued
Bear case: 12% overvalued
"The proposed merger of equals with Axalta, which targets about $600 million of cost synergies and 100 to 200 basis points of revenue synergies, could deliver stronger combined profitability and cash generation than investors currently expect…"
Read the full Bear Case to see why Akzo Nobel could be overvalued
Do you think there's more to the story for Akzo Nobel? Head over to our Community to see what others are saying!
The Bottom Line
Akzo Nobel screens as undervalued on both the Discounted Cash Flow (DCF) intrinsic value estimate and on earnings multiples, which points to a consistent message from the valuation work. The key question is whether the planned Axalta merger and the associated integration risks change the cash flow path enough to justify that discount. For now, the debate largely comes down to whether Akzo Nobel can deliver on efficiency, margins and merger execution. The answer to that will decide whether the current discount reflects mispricing or a fair cushion for the risks.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include AKZA.AS .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
